Clinical trials
Phase 1 Kidney Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 6 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
| Terminated | 8 |
| Recruiting | 6 |
| Withdrawn | 5 |
| Active, not recruiting | 3 |
| Not yet recruiting | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 5 |
| Brigham and Women's Hospital | 3 |
| Celldex Therapeutics | 3 |
| Incyte Corporation | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Pfizer | 3 |
| Amgen | 2 |
| Asan Medical Center | 2 |
| Bayer | 2 |
| Cumberland Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Diseases | 85 |
| Renal Insufficiency | 30 |
| Kidney Failure, Chronic | 16 |
| Renal Insufficiency, Chronic | 12 |
| Urologic Diseases | 10 |
| Kidney Neoplasms | 8 |
| Carcinoma, Renal Cell | 7 |
| Diabetes Mellitus | 5 |
| Neoplasms | 5 |
| Proteinuria | 4 |
Trials
Showing 26 to 50 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.